These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 2882787)

  • 21. Neuroleptic induced parkinsonism: MRI findings in relation to clinical course after withdrawal of neuroleptic drugs.
    Bocola V; Fabbrini G; Sollecito A; Paladini C; Martucci N
    J Neurol Neurosurg Psychiatry; 1996 Feb; 60(2):213-6. PubMed ID: 8708659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of parkinsonism and antiparkinsonian therapy in the subsequent development of tardive dyskinesia.
    Elliott KJ; Lewis S; el-Mallakh RS; Looney SW; Caudill R; Bacani-Oropilla T
    Ann Clin Psychiatry; 1994 Sep; 6(3):197-203. PubMed ID: 7881501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tardive dyskinesia as a risk factor for negative symptoms.
    Taylor SJ
    Br J Psychiatry; 1994 May; 164(5):701-2. PubMed ID: 7921732
    [No Abstract]   [Full Text] [Related]  

  • 24. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions.
    Dean CE; Kuskowski MA; Caligiuri MP
    J Clin Psychopharmacol; 2006 Dec; 26(6):560-5. PubMed ID: 17110811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tardive dyskinesia, mild drug-induced dyskinesia, and drug-induced parkinsonism: risk factors and topographic distribution.
    Akbostanci MC; Atbaşoğlu EC; Balaban H
    Acta Neurol Belg; 1999 Sep; 99(3):176-81. PubMed ID: 10544725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors for drug-induced parkinsonism in tardive dyskinesia patients.
    Hansen TE; Brown WL; Weigel RM; Casey DE
    J Clin Psychiatry; 1988 Apr; 49(4):139-41. PubMed ID: 2895762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of electroconvulsive therapy for drug-induced parkinsonism in the elderly.
    Sadananda SK; Holla B; Viswanath B; Narasimha A; Sebastian A; Math SB; Chandrashekar CR
    J ECT; 2013 Mar; 29(1):e6-7. PubMed ID: 23422531
    [No Abstract]   [Full Text] [Related]  

  • 28. High-dose destyrosine-gamma-endorphin in tardive dyskinesia.
    Korsgaard S; Casey DE; Gerlach J
    Psychopharmacology (Berl); 1982; 78(3):285-6. PubMed ID: 6130557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative neurochemical investigation of tardive dyskinesia and neuroleptic-induced chronic parkinsonism.
    Arató M; Bagdy G; Perényi A; Béla A
    Psychiatry Res; 1984 Apr; 11(4):347-51. PubMed ID: 6146151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cognitive performance of medicated schizophrenics with tardive dyskinesia.
    Collerton D; Fairbairn A; Britton P
    Psychol Med; 1985 May; 15(2):311-5. PubMed ID: 2862650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ventricular enlargement, clinical correlates and treatment outcome in chronic schizophrenic inpatients.
    Wilms G; Van Ongeval C; Baert AL; Claus A; Bollen J; De Cuyper H; Eneman M; Malfroid M; Peuskens J; Heylen S
    Acta Psychiatr Scand; 1992 Apr; 85(4):306-12. PubMed ID: 1375802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lateral ventricular size, psychopathology, and medication response in the psychoses.
    Luchins DJ; Lewine RR; Meltzer HY
    Biol Psychiatry; 1984 Jan; 19(1):29-44. PubMed ID: 6142730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tardive dyskinesia and neuroleptic-induced parkinsonism in Japan.
    Binder RL; Kazamatsuri H; Nishimura T; McNiel DE
    Am J Psychiatry; 1987 Nov; 144(11):1494-6. PubMed ID: 2890308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients.
    Richardson MA; Haugland G; Craig TJ
    Am J Psychiatry; 1991 Oct; 148(10):1322-8. PubMed ID: 1680296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of negative symptoms with tardive dyskinesia in schizophrenic patients.
    Chiu H; Lau J; Lam L; Shum P
    Aust N Z J Psychiatry; 1993 Jun; 27(2):228-32. PubMed ID: 8103320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Neuroleptics and nicotine].
    Erdmann R
    Psychiatr Prax; 1995 Nov; 22(6):223-7. PubMed ID: 8570751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relation of neuroleptic dose and tardive dyskinesia to attention, information-processing, and psychophysiology in medicated schizophrenics.
    Spohn HE; Coyne L; Lacoursiere R; Mazur D; Hayes K
    Arch Gen Psychiatry; 1985 Sep; 42(9):849-59. PubMed ID: 2864028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patterns of manual dominance in patients with neuroleptic-induced movement disorders.
    Kern RS; Green MF; Satz P; Wirshing WC
    Biol Psychiatry; 1991 Sep; 30(5):483-92. PubMed ID: 1681944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical association of tardive dyskinesia and drug-induced parkinsonism.
    Wolf ME; Chevesich J; Lehrer E; Mosnaim AD
    Biol Psychiatry; 1983 Oct; 18(10):1181-8. PubMed ID: 6140032
    [No Abstract]   [Full Text] [Related]  

  • 40. HLA antigens in drug-induced parkinsonism.
    Metzer WS; Newton JE; Steele RW; Claybrook M; Paige SR; McMillan DE; Hays S
    Mov Disord; 1989; 4(2):121-8. PubMed ID: 2567491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.